Evelo Biosciences
A clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intestinal axis, SINTAX, with systemic therapeutic effects.
The company’s product candidates are pharmaceutical preparations of single strains of microbes or their extracellular vesicles (EVs).
If shown to be effective in inflammatory disease mediated by the Th1, Th2 or Th17 inflammatory pathways, these same investigational medicines could be effective in additional inflammatory diseases, such as psoriatic and other forms of arthritis, asthma, allergy, and inflammatory bowel disease.
Latest Evelo Biosciences News & Features
22 November 2023
18 October 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze